article thumbnail

University of Melbourne reveals design of new infectious disease institute

Pharmaceutical Technology

The new AIID building will include a human infection challenge unit, high-containment facilities, a robotic biobanking facility, interview rooms, dry laboratories and spaces for community engagement and co-design work. It will be located at 766–780 Elizabeth Street and 213–223 Berkely Street in the Melbourne biomedical precinct.

article thumbnail

Why early participant engagement is now a top priority in genetic disease research

pharmaphorum

The DNA of these so-called ‘genetic superheroes’ may contain clues about how to treat severe disease. In our experience of running 20+ precision medicine studies, there are a few design principles that every research programme – from biobanks to clinical trials – should consider. Giving participants something in return.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Alnylam finds belly fat gene and drug target in UK Biobank study

pharmaphorum

The American Heart Association issued a statement last year highlighting the risks of visceral and abdominal fat (VAT), calling for clinical trials of therapies to reduce it, as well as greater efforts to encourage patients to exercise and improve their diets. Image by Bruno /Germany from Pixabay .

article thumbnail

Biorepositories as a Guiding Resource for Research & Drug Discovery

XTalks

Biobanks are used for the coordination of high-yield patient sample collection. Moreover, biobanks are no longer passive biorepositories for accrual of samples and serve a more utilitarian function in identifying and coordinating specific research cohorts for longitudinal and prospective studies. Biobanking Models.

article thumbnail

WORLD’S LARGEST BROWSABLE RESOURCE LINKING RARE PROTEIN-CODING GENETIC VARIANTS TO HUMAN HEALTH AND DISEASE

The Pharma Data

Managed by the Broad Institute of MIT and Harvard, the browser gives access to results from analyses of whole exome sequencing data from 300,000 UK Biobank research participants. PFIZER DISCLOSURE NOTICE: The information contained in this release is as of July 8, 2021. (Nasdaq: BIIB) and Pfizer (NYSE: PFE). Biogen Safe Harbor.

article thumbnail

Cryomacs Freezing Bags – A Critical Component in the Successful Delivery of Biological Samples and Therapies

Roots Analysis

While some biobanks ( especially non-clinical ones ) use mechanical freezers for storage, liquid nitrogen is one of the most reliable cryostorage mediums. Due to the infrastructure available for processing, freezing and storing of these container systems, blood bags are the preferred container for cell therapy biopreservation.

article thumbnail

HFpEF vs. HFrEF: How To Improve Heart Failure Drug Development

XTalks

Late-stage clinical trial failures are largely to blame for the lack of effective treatment options for patients with HFpEF, and poor five-year survival rates make this an area of great unmet need. A lack of efficacy is the greatest reason for clinical trial failures, especially in Phase II and Phase III,” says Dr. Tyl.